


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:32Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406545" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406545</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jmedcasrep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">476</journal-id><journal-id journal-id-type="pmc-domain">jmedcasrep</journal-id><journal-title-group><journal-title>Journal of Medical Case Reports</journal-title></journal-title-group><issn pub-type="epub">1752-1947</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406545</article-id><article-id pub-id-type="pmcid-ver">PMC12406545.1</article-id><article-id pub-id-type="pmcaid">12406545</article-id><article-id pub-id-type="pmcaiid">12406545</article-id><article-id pub-id-type="pmid">40898291</article-id><article-id pub-id-type="doi">10.1186/s13256-025-05517-3</article-id><article-id pub-id-type="publisher-id">5517</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Afebrile vancomycin-induced delayed hypersensitivity suggestive of incomplete drug rash with eosinophilia and systemic symptoms syndrome: a case report</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chou</surname><given-names initials="CH">Chien-Hung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="KC">Kun-Chuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kao</surname><given-names initials="CL">Chi-Lan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4522-8423</contrib-id><name name-style="western"><surname>Hong</surname><given-names initials="KJ">Kun-Jing</given-names></name><address><email>konjunhom@yahoo.com.tw</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03c8c9n80</institution-id><institution-id institution-id-type="GRID">grid.413535.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0627 9786</institution-id><institution>Department of Pharmacy, </institution><institution>Cathay General Hospital, </institution></institution-wrap>No.280, Sec. 4, Renai Rd., Daan Dist., Taipei, 106438 Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03c8c9n80</institution-id><institution-id institution-id-type="GRID">grid.413535.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0627 9786</institution-id><institution>Department of Neurosurgery, </institution><institution>Cathay General Hospital, </institution></institution-wrap>No.280, Sec. 4, Renai Rd., Daan Dist., Taipei, 106438 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03c8c9n80</institution-id><institution-id institution-id-type="GRID">grid.413535.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0627 9786</institution-id><institution>Department of Medical Research, </institution><institution>Cathay General Hospital, </institution></institution-wrap>No.280, Sec. 4, Renai Rd., Daan Dist., Taipei, 106438 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">478511</issue-id><elocation-id>439</elocation-id><history><date date-type="received"><day>3</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13256_2025_Article_5517.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Vancomycin-induced delayed hypersensitivity reactions are rare and typically accompanied by systemic symptoms such as fever, eosinophilia, and organ dysfunction, known as drug reaction with eosinophilia and systemic symptoms syndrome. However, nonsteroidal anti-inflammatory drugs can mask typical systemic signs, complicating diagnosis.</p></sec><sec><title>Case presentation</title><p id="Par2">A 61-year-old Asian Taiwanese male patient developed widespread erythematous macules and papules, significant skin desquamation, pruritus, and eosinophilia after 25&#160;days of vancomycin therapy initiated for suspected methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA)-related spondylodiscitis. Notably, the patient remained afebrile, likely owing to concurrent prolonged aceclofenac (nonsteroidal anti-inflammatory drug) usage, which masked the fever commonly associated with hypersensitivity reactions. Symptoms improved significantly after discontinuing vancomycin and initiating antihistamines and corticosteroid therapy.</p></sec><sec><title>Conclusion</title><p id="Par3">This case highlights an atypical presentation of vancomycin-induced delayed hypersensitivity with incomplete drug reaction with eosinophilia and systemic symptoms syndrome due to the absence of fever, potentially masked by nonsteroidal anti-inflammatory drug treatment. Clinicians should remain vigilant for atypical presentations of drug hypersensitivity reactions, especially in patients concurrently taking nonsteroidal anti-inflammatory drugs that can suppress fever.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13256-025-05517-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vancomycin</kwd><kwd>Delayed hypersensitivity</kwd><kwd>DRESS</kwd><kwd>NSAID</kwd><kwd>Eosinophilia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par4">Vancomycin is a glycopeptide antibiotic that is widely used for the treatment of severe Gram-positive infections, particularly methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) [<xref ref-type="bibr" rid="CR1">1</xref>]. In 2011, the Infectious Disease Society of America recommended vancomycin as a first-line drug for the treatment of MRSA infections in adults and children [<xref ref-type="bibr" rid="CR2">2</xref>]. Vancomycin-related side effects commonly include red man syndrome (RMS), neutropenia, fixed drug rash, fever, and nephrotoxicity. Less common but clinically significant adverse reactions such as leukocytoclastic vasculitis [<xref ref-type="bibr" rid="CR3">3</xref>], linear IgA bullous dermatosis (LABD) [<xref ref-type="bibr" rid="CR4">4</xref>], and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome [<xref ref-type="bibr" rid="CR5">5</xref>] have also been reported. Notably, vancomycin is recognized as one of the most commonly implicated antibiotics in the development of DRESS syndrome [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par5">Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, reduce fever, and relieve inflammation. NSAIDs are the first-line treatment for lower back pain and are effective in pain control following lumbar spine surgery [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. We report herein an atypical case of vancomycin-induced delayed hypersensitivity in a 61-year-old man who presented with erythematous macules and papules, desquamation, pruritus, and eosinophilia. Moreover, he had no fever because he took aceclofenac for pain control.</p></sec><sec id="Sec2"><title>Case summary</title><p id="Par6">A 61-year-old Asian Taiwanese male with history of Parkinson&#8217;s disease and benign prostatic hyperplasia presented to the emergency department owing to bilateral lower limb weakness following a fall. He reported longstanding lower back pain and intermittent numbness in both legs. Lumbar spinal stenosis and spondylolisthesis were diagnosed, and he underwent posterior spinal fusion surgery. Postoperatively, wound infection developed with persistent fever and purulent discharge, raising concern for MRSA-related spondylodiscitis. Vancomycin was initiated with a loading dose of 1 g followed by 500 mg every 6&#160;h (intravenous infusion&#8201;&gt;&#8201;1&#160;h), in combination with clindamycin 600&#160;mg every 8&#160;h. The patient was also receiving aceclofenac, a nonsteroidal anti-inflammatory drug (NSAID), for pain control throughout hospitalization (Supplementary Material 1).</p><p id="Par7">On day 44 of hospitalization, prior to vancomycin administration, the trough level was 14.02&#160;&#181;g/mL, and the white blood cell count was 5.47&#8201;&#215;&#8201;10<sup>3</sup>/&#181;L with 5.5% eosinophils. Approximately 6&#160;h after administration, the patient developed erythematous macules and papules on the arms and trunk without fever or hypotension. Vancomycin and aceclofenac were discontinued immediately, and levocetirizine 5&#160;mg daily was prescribed. Over the next 24&#160;h, the rash progressed to involve the face, neck, and lower extremities, accompanied by generalized desquamation and pruritus. A transient temperature elevation to 37.7&#160;&#176;C and mild hypotension (102/58&#160;mmHg) were observed, which improved following intramuscular diphenhydramine (30&#160;mg) and dexamethasone (5&#160;mg). On day 47 of hospitalization, surgical debridement of the postoperative wound was performed, and pus samples were collected for culture. Aceclofenac was reintroduced for pain control. Four days after discontinuation of vancomycin, erythematous macules and papules began to subside, while generalized desquamation and mild extremity edema persisted (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>The patient presented with erythematous macules and papules, desquamation, and mild bilateral edema in the lower limbs</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="13256_2025_5517_Fig1_HTML.jpg"/></fig></p><p id="Par8">On day 50 of hospitalization, the pus culture grew <italic toggle="yes">Pseudomonas aeruginosa</italic>. Therefore, trimethoprim/sulfamethoxazole (160&#160;mg/800&#160;mg, twice daily) and ciprofloxacin (400&#160;mg, every 12&#160;h) were substituted for clindamycin. On day 51, laboratory results showed a white blood cell count of 5.89&#8201;&#215;&#8201;10<sup>3</sup>/&#956;L, with 14.3% eosinophils and 2.9% atypical lymphocytes (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). By day 56, erythematous macules and papules had resolved, and edema had improved; however, desquamation persisted on the patient&#8217;s face, trunk, and extremities (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Fluocinonide and urea cream were applied twice daily to alleviate symptoms. As the patient&#8217;s pain improved and desquamation gradually subsided, he was discharged on day 79 of hospitalization.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Timeline of vancomycin administration and hematologic response. Vancomycin was initiated on hospital day 20 owing to clinical suspicion of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> infection. On day 44, it was discontinued immediately following the onset of vancomycin-induced delayed hypersensitivity. The blue line represents changes in white blood cell count, while the orange line represents eosinophil count throughout the clinical course. A detailed timeline of antimicrobial and nonsteroidal anti-inflammatory drug use is provided in Supplementary Material 3</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="13256_2025_5517_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>By day 56, the erythematous macules and papules had subsided, though desquamation persisted</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="13256_2025_5517_Fig3_HTML.jpg"/></fig></p><p id="Par9">To assess the likelihood of DRESS syndrome, we applied the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring system. The patient received a total score of 3, which falls under the category of &#8220;possible DRESS.&#8221; The score was based on the presence of eosinophilia (&#8805;&#8201;10%), suggestive skin eruption, and a latency period of more than 3&#160;weeks after starting vancomycin. Notably, there was no fever, no lymphadenopathy, and no definitive visceral organ involvement. Although serum creatinine increased slightly to 1.15&#160;mg/dL on day 58 (reference range 0.63&#8211;1.3&#160;mg/dL), it remained within normal limits and returned to baseline without intervention, suggesting only a transient and minor renal effect.</p></sec><sec id="Sec3"><title>Discussion and conclusion</title><p id="Par10">Drug hypersensitivity reactions are divided into immediate and delayed reactions. Immediate reactions typically appear within 1&#160;h of drug administration and are usually caused by immunoglobulin E (IgE)-mediated hypersensitivity or direct activation of mast cells. Delayed reactions appear from 1&#160;h after drug administration and may be due to antigen-specific IgG production, a T-cell mediated response, or complement activation [<xref ref-type="bibr" rid="CR8">8</xref>]. Drug-induced delayed reactions usually present as a rash accompanied by itching that starts on the trunk and spreads symmetrically to the extremities. In addition, some patients have systemic symptoms including fever, eosinophilia, lymphadenopathy, and organ failure [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par11">Vancomycin-induced delayed hypersensitivity may occur 48&#8211;96&#160;h after exposure in previously sensitized patients or up to 14&#160;days later in nonsensitized patients [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. In ten cases of vancomycin-related delayed cutaneous reactions reported by Korman et al., eight patients had fever and six had eosinophilia. The mean onset of the delayed reactions was 20.1&#160;days (range 6&#8211;31&#160;days) after starting vancomycin [<xref ref-type="bibr" rid="CR14">14</xref>]. Marik and Ferris reported a 51-year-old man who had high fever, erythema multiforme, eosinophilia, and presumed interstitial nephritis about 4&#160;weeks after starting vancomycin [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par12">We also distinguished between vancomycin-induced delayed hypersensitivity and RMS. RMS is a histamine-mediated infusion reaction characterized by pruritic, erythematous rash typically involving the face, neck, and upper torso, and may be accompanied by flushing, hypotension, angioedema, or dyspnea. It usually occurs within 4&#8211;10&#160;min of initiating vancomycin infusion or shortly thereafter, particularly during rapid parenteral administration at rates exceeding 10&#160;mg/minute. Although RMS most commonly presents with the first dose, it can occasionally appear later in therapy, even in patients who have previously tolerated the drug [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Symptoms usually resolve within 20&#160;minutes but may persist for several hours in some cases [<xref ref-type="bibr" rid="CR1">1</xref>]. In contrast, the timing and persistence of the rash&#8212;appearing 6&#160;hours post-infusion and lasting 12&#160;days&#8212;suggest that the clinical presentation in our case differs from that of RMS.</p><p id="Par13">Beyond RMS, another important differential diagnosis for delayed cutaneous reactions is drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. DRESS syndrome is a severe and idiosyncratic form of delayed hypersensitivity, typically presenting 2&#8211;6&#160;weeks after the initiation of the offending drug [<xref ref-type="bibr" rid="CR18">18</xref>]. According to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria, diagnosis requires an acute drug-related rash accompanied by at least three of the following systemic features: fever &gt;&#8201;38&#160;&#176;C, lymphadenopathy, internal organ involvement, or hematologic abnormalities such as eosinophilia or atypical lymphocytosis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Differentiating DRESS syndrome from simple drug hypersensitivity reactions is crucial owing to its more complex clinical course and worse prognosis. While simple reactions are generally confined to the skin and resolve promptly after drug cessation, DRESS syndrome is often associated with prolonged fever and systemic involvement, and may require extended immunosuppressive therapy [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In our case, the patient presented with extensive desquamation and marked eosinophilia but lacked persistent fever, lymphadenopathy, or evidence of visceral organ dysfunction. The rapid improvement following corticosteroid therapy and the absence of internal organ involvement support classifying this case as an incomplete or possible form of DRESS syndrome rather than classic DRESS syndrome.</p><p id="Par14">Cabrera Hernandez <italic toggle="yes">et al.</italic> recently reported delayed hypersensitivity associated with clindamycin [<xref ref-type="bibr" rid="CR22">22</xref>]. Although vancomycin and clindamycin were co-administered in our case, clindamycin was continued for 6&#160;days after vancomycin was ceased. The patient&#8217;s trunk rashes improved during these 6&#160;days. Therefore, clindamycin was excluded as a cause of the delayed hypersensitivity reactions.</p><p id="Par15">Patients with a hypersensitivity reaction to vancomycin must discontinue the drug immediately. Corticosteroids have been used in the treatment of vancomycin-induced delayed hypersensitivity and vancomycin-associated DRESS syndrome [<xref ref-type="bibr" rid="CR23">23</xref>]. In our case, the symptoms resolved with discontinuation of vancomycin and treatment with antihistamines and corticosteroids. According to the Naranjo adverse drug reaction probability scale, vancomycin was a probable cause of delayed hypersensitivity (Naranjo score: 7 points) [<xref ref-type="bibr" rid="CR24">24</xref>] (Supplementary Material 2).</p><p id="Par16">Although the patient demonstrated extensive desquamation and marked eosinophilia, hallmark features of DRESS syndrome such as sustained fever and lymphadenopathy were absent. This atypical presentation raised concerns about potential confounding factors that may have masked systemic signs. In particular, the patient was receiving aceclofenac concurrently during the symptomatic period, which could have suppressed febrile responses and obscured the classic clinical picture of DRESS syndrome. Aceclofenac is an oral NSAID with potent anti-inflammatory, analgesic, and antipyretic properties. It is commonly prescribed for musculoskeletal conditions such as lower back pain [<xref ref-type="bibr" rid="CR25">25</xref>]. In our case, erythematous macules and papules initially developed on the arms and trunk 25&#160;days after vancomycin initiation. The following day, the condition worsened significantly, with the rash spreading to the face, neck, and lower extremities, accompanied by generalized desquamation. Despite the severity of cutaneous symptoms, the patient remained afebrile, likely owing to the antipyretic effect of aceclofenac.</p><p id="Par17">This is an atypical case of vancomycin-induced delayed hypersensitivity, which presented with no fever owing to prolonged use of NSAID. We suggest that health professionals should be alert to the different manifestations of delayed hypersensitivity in patients treated with vancomycin, especially in conjunction with NSAIDs, which may mask hypersensitivity-related fever. If there are any early symptoms of hypersensitivity, patients should be monitored closely to prevent delays in treatment.</p></sec><sec id="Sec4" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="13256_2025_5517_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="13256_2025_5517_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xlink:href="13256_2025_5517_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 3.</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We express our gratitude to Cathay General Hospital for support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed substantially to the manuscript&#8217;s development, including conceptualization, writing, and editing. Conceptualization and design: Chien-Hung Chou, Kun-Jing Hong; part of the treating team and data collection and data analysis: Chien-Hung Chou, Kun-Chuan Chang, Chi-Lan Kao; revision of the manuscript drafts: Chien-Hung Chou, Kun-Jing Hong. The submitted version of the manuscript has been approved by all authors, who have also agreed to take responsibility for any aspect of the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data are not publicly available due to privacy or ethical restrictions.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par18">This study was approved by the Institutional Review Board of the Cathay General Hospital (CGH-P109072).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par19">Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par20">The authors declare that they have no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruniera</surname><given-names>FR</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>FM</given-names></name><name name-style="western"><surname>Saviolli</surname><given-names>LR</given-names></name><name name-style="western"><surname>Bacci</surname><given-names>MR</given-names></name><name name-style="western"><surname>Feder</surname><given-names>D</given-names></name><name name-style="western"><surname>da Luz Gon&#231;alves Pedreira</surname><given-names>M</given-names></name><etal/></person-group><article-title>The use of vancomycin with its therapeutic and adverse effects: a review</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2015</year><volume>19</volume><issue>4</issue><fpage>694</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">25753888</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bruniera FR, Ferreira FM, Saviolli LR, Bacci MR, Feder D, da Luz Gon&#231;alves Pedreira M, <italic toggle="yes">et al</italic>. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015;19(4):694&#8211;700.<pub-id pub-id-type="pmid">25753888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>A</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>SE</given-names></name><name name-style="western"><surname>Daum</surname><given-names>RS</given-names></name><name name-style="western"><surname>Fridkin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gorwitz</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <italic toggle="yes">Staphylococcus</italic>
<italic toggle="yes">aureus</italic> infections in adults and children: executive summary</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">21217178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cir034</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, <italic toggle="yes">et al</italic>. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <italic toggle="yes">Staphylococcus</italic><italic toggle="yes">aureus</italic> infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285&#8211;92.<pub-id pub-id-type="pmid">21217178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cir034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zadroga</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mogulla</surname><given-names>V</given-names></name><name name-style="western"><surname>Grant</surname><given-names>C</given-names></name><name name-style="western"><surname>Jevtic</surname><given-names>D</given-names></name><name name-style="western"><surname>Virata</surname><given-names>A</given-names></name><name name-style="western"><surname>Dumic</surname><given-names>I</given-names></name></person-group><article-title>The many faces of purpura: vancomycin-induced leukocytoclastic vasculitis</article-title><source>Case Rep Infect Dis</source><year>2021</year><volume>4</volume><issue>2021</issue><fpage>9932425</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9932425</pub-id><pub-id pub-id-type="pmcid">PMC8203330</pub-id><pub-id pub-id-type="pmid">34194855</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zadroga JA, Mogulla V, Grant C, Jevtic D, Virata A, Dumic I. The many faces of purpura: vancomycin-induced leukocytoclastic vasculitis. Case Rep Infect Dis. 2021;4(2021):9932425.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9932425</pub-id><pub-id pub-id-type="pmcid">PMC8203330</pub-id><pub-id pub-id-type="pmid">34194855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visentainer</surname><given-names>L</given-names></name><name name-style="western"><surname>Massuda</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cintra</surname><given-names>ML</given-names></name><name name-style="western"><surname>Magalh&#227;es</surname><given-names>RF</given-names></name></person-group><article-title>Vancomycin-induced linear IgA bullous dermatosis (LABD)-an atypical presentation</article-title><source>Clin Case Rep</source><year>2019</year><volume>7</volume><issue>5</issue><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">31110752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ccr3.2039</pub-id><pub-id pub-id-type="pmcid">PMC6509886</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Visentainer L, Massuda JY, Cintra ML, Magalh&#227;es RF. Vancomycin-induced linear IgA bullous dermatosis (LABD)-an atypical presentation. Clin Case Rep. 2019;7(5):1091&#8211;3.<pub-id pub-id-type="pmid">31110752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ccr3.2039</pub-id><pub-id pub-id-type="pmcid">PMC6509886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharifzadeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Mohammadpour</surname><given-names>AH</given-names></name><name name-style="western"><surname>Tavanaee</surname><given-names>A</given-names></name><name name-style="western"><surname>Elyasi</surname><given-names>S</given-names></name></person-group><article-title>Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review</article-title><source>Eur J Clin Pharmacol</source><year>2021</year><volume>77</volume><issue>3</issue><fpage>275</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">33025080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-020-03005-9</pub-id><pub-id pub-id-type="pmcid">PMC7537982</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S. Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol. 2021;77(3):275&#8211;89.<pub-id pub-id-type="pmid">33025080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-020-03005-9</pub-id><pub-id pub-id-type="pmcid">PMC7537982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>R</given-names></name><name name-style="western"><surname>Qaseem</surname><given-names>A</given-names></name><name name-style="western"><surname>Snow</surname><given-names>V</given-names></name><name name-style="western"><surname>Casey</surname><given-names>D</given-names></name><name name-style="western"><surname>Cross</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Shekelle</surname><given-names>P</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><issue>7</issue><fpage>478</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">17909209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-147-7-200710020-00006</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, Shekelle P, <italic toggle="yes">et al</italic>. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478&#8211;91.<pub-id pub-id-type="pmid">17909209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-147-7-200710020-00006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nonsteroidal anti-inflammatory drugs for postoperative pain control after lumbar spine surgery: a meta-analysis of randomized controlled trials</article-title><source>J Clin Anesth</source><year>2017</year><volume>43</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">29046234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinane.2017.08.030</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Zhang Z, Xu H, Zhang Y, Li W, Yang Y, Han T, <italic toggle="yes">et al</italic>. Nonsteroidal anti-inflammatory drugs for postoperative pain control after lumbar spine surgery: a meta-analysis of randomized controlled trials. J Clin Anesth. 2017;43:84&#8211;9.<pub-id pub-id-type="pmid">29046234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinane.2017.08.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franceschini</surname><given-names>F</given-names></name><name name-style="western"><surname>Bottau</surname><given-names>P</given-names></name><name name-style="western"><surname>Caimmi</surname><given-names>S</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>F</given-names></name><name name-style="western"><surname>Crisafulli</surname><given-names>G</given-names></name><name name-style="western"><surname>Liotti</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mechanisms of hypersensitivity reactions induced by drugs</article-title><source>Acta Biomed</source><year>2019</year><volume>90</volume><issue>3-S</issue><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">30830061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23750/abm.v90i3-S.8160</pub-id><pub-id pub-id-type="pmcid">PMC6502177</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Franceschini F, Bottau P, Caimmi S, Cardinale F, Crisafulli G, Liotti L, <italic toggle="yes">et al</italic>. Mechanisms of hypersensitivity reactions induced by drugs. Acta Biomed. 2019;90(3-S):44&#8211;51.<pub-id pub-id-type="pmid">30830061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23750/abm.v90i3-S.8160</pub-id><pub-id pub-id-type="pmcid">PMC6502177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardern-Jones</surname><given-names>MR</given-names></name><name name-style="western"><surname>Friedmann</surname><given-names>PS</given-names></name></person-group><article-title>Skin manifestations of drug allergy</article-title><source>Br J Clin Pharmacol</source><year>2011</year><volume>71</volume><issue>5</issue><fpage>672</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">21480947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2010.03703.x</pub-id><pub-id pub-id-type="pmcid">PMC3093073</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol. 2011;71(5):672&#8211;83.<pub-id pub-id-type="pmid">21480947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2010.03703.x</pub-id><pub-id pub-id-type="pmcid">PMC3093073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkerson</surname><given-names>RG</given-names></name></person-group><article-title>Drug hypersensitivity reactions</article-title><source>Immunol Allergy Clin North Am</source><year>2023</year><volume>43</volume><issue>3</issue><fpage>473</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">37394254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.iac.2022.10.005</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wilkerson RG. Drug hypersensitivity reactions. Immunol Allergy Clin North Am. 2023;43(3):473&#8211;89.<pub-id pub-id-type="pmid">37394254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.iac.2022.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Legendre</surname><given-names>DP</given-names></name><name name-style="western"><surname>Muzny</surname><given-names>CA</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>GD</given-names></name><name name-style="western"><surname>Swiatlo</surname><given-names>E</given-names></name></person-group><article-title>Antibiotic hypersensitivity reactions and approaches to desensitization</article-title><source>Clin Infect Dis</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>1140</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">24368623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cit949</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Legendre DP, Muzny CA, Marshall GD, Swiatlo E. Antibiotic hypersensitivity reactions and approaches to desensitization. Clin Infect Dis. 2014;58(8):1140&#8211;8.<pub-id pub-id-type="pmid">24368623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cit949</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minhas</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wickner</surname><given-names>PG</given-names></name><name name-style="western"><surname>Long</surname><given-names>AA</given-names></name><name name-style="western"><surname>Banerji</surname><given-names>A</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>KG</given-names></name></person-group><article-title>Immune-mediated reactions to vancomycin: a systematic case review and analysis</article-title><source>Ann Allergy Asthma Immunol</source><year>2016</year><volume>116</volume><issue>6</issue><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">27156746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anai.2016.03.030</pub-id><pub-id pub-id-type="pmcid">PMC4946960</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Minhas JS, Wickner PG, Long AA, Banerji A, Blumenthal KG. Immune-mediated reactions to vancomycin: a systematic case review and analysis. Ann Allergy Asthma Immunol. 2016;116(6):544&#8211;53.<pub-id pub-id-type="pmid">27156746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anai.2016.03.030</pub-id><pub-id pub-id-type="pmcid">PMC4946960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>V</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>NA</given-names></name><name name-style="western"><surname>Welker</surname><given-names>KH</given-names></name></person-group><article-title>Glycopeptide hypersensitivity and adverse reactions</article-title><source>Pharmacy (Basel)</source><year>2020</year><volume>8</volume><issue>2</issue><fpage>70</fpage><pub-id pub-id-type="pmid">32326261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmacy8020070</pub-id><pub-id pub-id-type="pmcid">PMC7357119</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Huang V, Clayton NA, Welker KH. Glycopeptide hypersensitivity and adverse reactions. Pharmacy (Basel). 2020;8(2): 70.<pub-id pub-id-type="pmid">32326261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmacy8020070</pub-id><pub-id pub-id-type="pmcid">PMC7357119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korman</surname><given-names>TM</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>JD</given-names></name><name name-style="western"><surname>Grayson</surname><given-names>ML</given-names></name></person-group><article-title>Risk factors for adverse cutaneous reactions associated with intravenous vancomycin</article-title><source>J Antimicrob Chemother</source><year>1997</year><volume>39</volume><issue>3</issue><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">9096187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.jac.a020861</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Korman TM, Turnidge JD, Grayson ML. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother. 1997;39(3):371&#8211;81.<pub-id pub-id-type="pmid">9096187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.jac.a020861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marik</surname><given-names>PE</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>N</given-names></name></person-group><article-title>Delayed hypersensitivity reaction to vancomycin</article-title><source>Pharmacotherapy</source><year>1997</year><volume>17</volume><issue>6</issue><fpage>1341</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">9399623</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. Pharmacotherapy. 1997;17(6):1341&#8211;4.<pub-id pub-id-type="pmid">9399623</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivagnanam</surname><given-names>S</given-names></name><name name-style="western"><surname>Deleu</surname><given-names>D</given-names></name></person-group><article-title>Red man syndrome</article-title><source>Crit Care</source><year>2003</year><volume>7</volume><issue>2</issue><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">12720556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc1871</pub-id><pub-id pub-id-type="pmcid">PMC270616</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119&#8211;20.<pub-id pub-id-type="pmid">12720556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc1871</pub-id><pub-id pub-id-type="pmcid">PMC270616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dykewicz</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lam</surname><given-names>JK</given-names></name></person-group><article-title>Drug hypersensitivity reactions</article-title><source>Med Clin North Am</source><year>2020</year><volume>104</volume><issue>1</issue><fpage>109</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">31757230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2019.09.003</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Dykewicz MS, Lam JK. Drug hypersensitivity reactions. Med Clin North Am. 2020;104(1):109&#8211;28.<pub-id pub-id-type="pmid">31757230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2019.09.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calle</surname><given-names>AM</given-names></name><name name-style="western"><surname>Aguirre</surname><given-names>N</given-names></name><name name-style="western"><surname>Ardila</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>VR</given-names></name></person-group><article-title>DRESS syndrome: a literature review and treatment algorithm</article-title><source>World Allergy Organ J</source><year>2023</year><volume>16</volume><issue>3</issue><fpage>100673</fpage><pub-id pub-id-type="pmid">37082745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.waojou.2022.100673</pub-id><pub-id pub-id-type="pmcid">PMC10112187</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Calle AM, Aguirre N, Ardila JC, Cardona VR. DRESS syndrome: a literature review and treatment algorithm. World Allergy Organ J. 2023;16(3): 100673.<pub-id pub-id-type="pmid">37082745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.waojou.2022.100673</pub-id><pub-id pub-id-type="pmcid">PMC10112187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>SA</given-names></name><name name-style="western"><surname>Creamer</surname><given-names>D</given-names></name></person-group><article-title>Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking</article-title><source>Clin Exp Dermatol</source><year>2011</year><volume>36</volume><issue>1</issue><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21143513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2010.03967.x</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6&#8211;11.<pub-id pub-id-type="pmid">21143513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2010.03967.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>YT</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chu</surname><given-names>CY</given-names></name></person-group><article-title>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an interplay among drugs, viruses, and immune system</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><issue>6</issue><fpage>1243</fpage><pub-id pub-id-type="pmid">28598363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18061243</pub-id><pub-id pub-id-type="pmcid">PMC5486066</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017;18(6):1243.<pub-id pub-id-type="pmid">28598363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18061243</pub-id><pub-id pub-id-type="pmcid">PMC5486066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>A</given-names></name><name name-style="western"><surname>Rajagopalan</surname><given-names>M</given-names></name><name name-style="western"><surname>Sarda</surname><given-names>A</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>P</given-names></name></person-group><article-title>Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature</article-title><source>Indian J Dermatol</source><year>2018</year><volume>63</volume><issue>1</issue><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">29527023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijd.IJD_582_17</pub-id><pub-id pub-id-type="pmcid">PMC5838752</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol. 2018;63(1):30&#8211;40.<pub-id pub-id-type="pmid">29527023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijd.IJD_582_17</pub-id><pub-id pub-id-type="pmcid">PMC5838752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera Hernandez</surname><given-names>V</given-names></name><name name-style="western"><surname>Gonzalez Afonso</surname><given-names>M</given-names></name><name name-style="western"><surname>Callero Viera</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin-Fernandez Martin</surname><given-names>L</given-names></name></person-group><article-title>Symmetrical drug-related intertriginous and flexural exanthema due to clindamycin</article-title><source>BMJ Case Rep</source><year>2019</year><volume>12</volume><issue>8</issue><fpage>e230077</fpage><pub-id pub-id-type="pmid">31377719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2019-230077</pub-id><pub-id pub-id-type="pmcid">PMC6685379</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Cabrera Hernandez V, Gonzalez Afonso M, Callero Viera A, Martin-Fernandez Martin L. Symmetrical drug-related intertriginous and flexural exanthema due to clindamycin. BMJ Case Rep. 2019;12(8): e230077.<pub-id pub-id-type="pmid">31377719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2019-230077</pub-id><pub-id pub-id-type="pmcid">PMC6685379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madigan</surname><given-names>LM</given-names></name><name name-style="western"><surname>Fox</surname><given-names>LP</given-names></name></person-group><article-title>Vancomycin-associated drug-induced hypersensitivity syndrome</article-title><source>J Am Acad Dermatol</source><year>2019</year><volume>81</volume><issue>1</issue><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">30738120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2019.02.002</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Madigan LM, Fox LP. Vancomycin-associated drug-induced hypersensitivity syndrome. J Am Acad Dermatol. 2019;81(1):123&#8211;8.<pub-id pub-id-type="pmid">30738120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2019.02.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naranjo</surname><given-names>CA</given-names></name><name name-style="western"><surname>Busto</surname><given-names>U</given-names></name><name name-style="western"><surname>Sellers</surname><given-names>EM</given-names></name><name name-style="western"><surname>Sandor</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>I</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>EA</given-names></name><etal/></person-group><article-title>A method for estimating the probability of adverse drug reactions</article-title><source>Clin Pharmacol Ther</source><year>1981</year><volume>30</volume><issue>2</issue><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">7249508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1981.154</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, <italic toggle="yes">et al</italic>. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239&#8211;45.<pub-id pub-id-type="pmid">7249508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1981.154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TK</given-names></name><name name-style="western"><surname>Kang</surname><given-names>CN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Evaluation of the efficacy and safety of NVP-1203 and aceclofenac in patients with acute low back pain and muscle spasm: a randomized, double-blind, active-controlled, parallel, multicenter, phase 3 clinical trial</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2023</year><volume>27</volume><issue>1</issue><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">36647880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202301_30878</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lee S, Kim HJ, Kim JH, Kim TK, Kang CN, Lee JH, <italic toggle="yes">et al</italic>. Evaluation of the efficacy and safety of NVP-1203 and aceclofenac in patients with acute low back pain and muscle spasm: a randomized, double-blind, active-controlled, parallel, multicenter, phase 3 clinical trial. Eur Rev Med Pharmacol Sci. 2023;27(1):315&#8211;24.<pub-id pub-id-type="pmid">36647880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202301_30878</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>